Group 1 - The core point of the article is that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has approved the spin-off of its subsidiary Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd. for a listing on the Hong Kong Stock Exchange [1] - The proposed initial issuance of H-shares will not exceed 25% of the total share capital after issuance, with an option for an additional 15% through an over-allotment [1] - The board believes that the spin-off aligns with regulatory requirements and will help the company focus on its core business, enhance independence, and unlock the valuation potential of its vaccine business segment [1] Group 2 - After the spin-off, Shanghai Fosun Pharmaceutical is expected to maintain control over Fosun Antigen [1] - Fosun Antigen serves as the vaccine business platform for Shanghai Fosun Pharmaceutical, engaging in the research, production, and sales of vaccines [1] - Currently, Fosun Antigen has launched products including human rabies vaccine and influenza virus split vaccine [1]

文/梧桐数据中心 12月6日IPO共审核2家公司（沪主板、北交所各1家），2家均获通过。 单位：万元 | | | 沪主板 | | | | --- | --- | --- | --- | --- | | 公司简称 主营业务 | 2023年营收 | 2023年净利润 | 审核结果 | 保荐/律所/审计 | | 汽车仪表的研发设计、 天有为 | 343,707.85 | 89.407.15 | 通过 | 中信建投/北京中伦/立信 | | 生产、销售和服务 | | | | | | | | 北交所 | | | | 主营业务 公司简称 | 2023年营收 | 2023年净利润 | 审核结果 | 保荐/律所/审计 | | 智能电、水、气表等智 能计量终端以及AMI系 开发科技 | 254,978.26 | 49,897.07 | 通过 | 华泰联合/北京中伦/立信 | | 统软件的研发、生产及 | | | | | | 销售 | | | | | 天有为 主要从事汽车仪表的研发设计、生产、销售和服务，并逐步向智能座舱领域拓展。王文博直接持有公司53.60%股份，为公司的控股股东；王文博、吕冬芳 夫妇合计控制公司91.49%股份 ...